Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -60,011 | 0 | N/A | N/A |
| Depreciation Amortization | 9 | 0 | N/A | N/A |
| Accounts payable and accrued liabilities | 1,961 | N/A | N/A | N/A |
| Other Working Capital | -111 | 0 | N/A | N/A |
| Other Operating Activity | 27,423 | 0 | 0 | 0 |
| Operating Cash Flow | $-30,729 | $0 | $N/A | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -82 | 0 | N/A | N/A |
| Purchase Sale Intangibles | -9,000 | N/A | N/A | N/A |
| Other Investing Activity | -9,000 | 0 | 0 | 0 |
| Investing Cash Flow | $-9,082 | $0 | $N/A | $N/A |
| Cash Flows From Financing Activities | ||||
| Debt Issued | 1,673 | N/A | N/A | N/A |
| Debt Repayment | -1,673 | N/A | N/A | N/A |
| Common Stock Issued | 165,854 | N/A | N/A | N/A |
| Other Financing Activity | 125,210 | 0 | 0 | 0 |
| Financing Cash Flow | $291,064 | $0 | $N/A | $N/A |
| End Cash Position | 251,253 | 0 | N/A | N/A |
| Net Cash Flow | $251,253 | $0 | $N/A | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -30,729 | 0 | N/A | N/A |
| Capital Expenditure | -82 | N/A | N/A | N/A |
| Free Cash Flow | -30,811 | 0 | 0 | 0 |